Rhythm Pharmaceuticals Reports Positive Phase 2 Results for PWS Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Trial Results: In a trial involving 17 patients with Prader-Willi syndrome (PWS), treatment with setmelanotide resulted in a mean BMI reduction of 3.06%, with 6 out of 10 adult patients achieving over 2.5% BMI reduction, indicating the therapy's effectiveness in weight management and potential improvement in patients' quality of life.
- Body Composition Improvement: Among 16 patients assessed via DEXA scans, setmelanotide led to a mean gain of 0.74% in lean mass and a mean loss of 4.19% in fat mass, demonstrating the drug's ability to facilitate weight loss while preserving muscle mass, thereby enhancing overall health outcomes for patients.
- Emotional and Behavioral Improvements: Of the 15 patients with baseline anxiety scores above 11, 10 achieved significant improvements in anxiety and emotional distress measures, suggesting the therapy's potential to alleviate psychological burdens for both patients and their caregivers.
- Future Development Plans: Following these positive results, Rhythm Pharmaceuticals intends to advance setmelanotide into Phase 3 trials for PWS, further validating its long-term efficacy and safety, reflecting the company's strategic commitment to addressing rare diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RYTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RYTM
Wall Street analysts forecast RYTM stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 87.660
Low
123.00
Averages
140.62
High
167.00
Current: 87.660
Low
123.00
Averages
140.62
High
167.00
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rhythm Pharmaceuticals to Host Conference Call on Interim Phase 2 Results
- Interim Results Announcement: Rhythm Pharmaceuticals will host a conference call on June 13 to discuss interim six-month results from its Phase 2 trial for Prader-Willi syndrome, which is expected to attract attention from investors and healthcare professionals, potentially impacting the company's stock price.
- Leadership Participation: The call will feature insights from CEO David Meeker, M.D., and Dr. Jennifer Miller from the University of Florida, enhancing market confidence in the company's clinical progress and possibly fostering positive investor sentiment about future prospects.
- IMCIVREE Drug Information: Rhythm's lead asset, IMCIVREE, has received FDA approval for treating obesity related to genetic conditions, and this meeting is anticipated to clarify its market applications, potentially driving sales growth.
- Clinical Development Plans: The company is advancing clinical development for IMCIVREE in other rare diseases, showcasing its innovative capabilities in the biopharmaceutical sector, which may lay the groundwork for future product line expansions.
See More
Rhythm Pharmaceuticals Reports Positive Phase 2 Results for PWS Treatment
- Clinical Trial Results: In a trial involving 17 patients with Prader-Willi syndrome (PWS), treatment with setmelanotide resulted in a mean BMI reduction of 3.06%, with 6 out of 10 adult patients achieving over 2.5% BMI reduction, indicating the therapy's effectiveness in weight management and potential improvement in patients' quality of life.
- Body Composition Improvement: Among 16 patients assessed via DEXA scans, setmelanotide led to a mean gain of 0.74% in lean mass and a mean loss of 4.19% in fat mass, demonstrating the drug's ability to facilitate weight loss while preserving muscle mass, thereby enhancing overall health outcomes for patients.
- Emotional and Behavioral Improvements: Of the 15 patients with baseline anxiety scores above 11, 10 achieved significant improvements in anxiety and emotional distress measures, suggesting the therapy's potential to alleviate psychological burdens for both patients and their caregivers.
- Future Development Plans: Following these positive results, Rhythm Pharmaceuticals intends to advance setmelanotide into Phase 3 trials for PWS, further validating its long-term efficacy and safety, reflecting the company's strategic commitment to addressing rare diseases.
See More
Stock Investment Opportunities in May
- TransMedics' Bright Outlook: Despite TransMedics Group (NASDAQ: TMDX) reporting Q1 earnings per share of $0.30, below the expected $0.61, its revenue increased by 21% year-over-year, indicating strong long-term potential in organ transplant technology, especially with plans for European expansion.
- Rhythm Pharmaceuticals' Recovery: Rhythm Pharmaceuticals (NASDAQ: RYTM) recently secured FDA and European Commission approvals for Imcivree, which is expected to boost its stock price, while Japanese regulators are also reviewing the drug, impacting over 25,000 patients and highlighting significant market potential.
- Enbridge's Stable Returns: Enbridge (NYSE: ENB), as North America's largest natural gas utility, transports 30% of crude oil and one-fifth of natural gas, providing stable investment returns, with an attractive 5.2% dividend yield that stands out in the energy sector.
- Long-Term Growth Opportunities: Enbridge's management anticipates approximately $50 billion in growth opportunities by 2030, with investment decisions for $10 billion to $20 billion expected in the next 24 months, offering solid growth prospects despite being less explosive than TransMedics and Rhythm.
See More
Rhythm Pharmaceuticals Reports Strong Earnings, IMCIVREE Demand Surges
- Earnings Beat Expectations: Rhythm Pharmaceuticals reported quarterly earnings that exceeded market expectations, reflecting strong performance in drug sales, which is likely to boost investor confidence moving forward.
- Strong Demand for IMCIVREE: The demand for IMCIVREE continues to grow, driving revenue increases and indicating a rising market acceptance of the drug in the treatment landscape, potentially laying the groundwork for future revenue growth.
- International Market Expansion Potential: The company plans to launch IMCIVREE in Europe and Japan, and successful entry into these markets could significantly broaden its international business footprint and enhance its competitive position globally.
- Strategic Growth Outlook: Rhythm Pharmaceuticals' robust performance and international expansion plans suggest that its strategic decisions to meet global patient needs will contribute to long-term growth and an increase in market share.
See More
Rhythm Pharmaceuticals Surges 8% After Strong Quarterly Earnings Report
- Significant Revenue Growth: Rhythm Pharmaceuticals reported a nearly doubled revenue of $60.1 million in Q1, driven by its Imcivree drug, surpassing the analyst consensus estimate of $57 million, indicating strong market performance in the weight-loss sector.
- Improved Net Loss: The company's net loss widened to $56.7 million (or $0.83 per share), yet it was better than the expected loss of $0.86, suggesting some progress in cost management despite increased expenses.
- Accelerated Market Promotion: Following FDA approval for a new indication (hypothalamic obesity), Imcivree received over 150 patient start forms within six weeks, demonstrating robust market demand and rapid promotional capabilities.
- Strong European Market Performance: Rhythm's revenue in Europe surged by 27% quarter-over-quarter, primarily driven by strong demand in key markets like Germany and France, further boosting investor confidence in the company's growth prospects.
See More
Rhythm Pharmaceuticals Q1 2026 Earnings Call Highlights
- Revenue Growth: Rhythm Pharmaceuticals reported global net revenues of $60.1 million for Q1 2026, reflecting a 5% sequential increase from Q4 2025, indicating robust market performance, particularly with 61% of revenue generated in the U.S.
- IMCIVREE Launch Status: Since the FDA approval of IMCIVREE, the company has received over 150 start forms, with approximately 80% coming from new prescribers, demonstrating strong market reception and potential for future revenue growth.
- R&D and Expense Outlook: The company anticipates non-GAAP operating expenses for fiscal year 2026 to be between $385 million and $415 million, with R&D expenses projected at $197 million to $213 million, reflecting a commitment to ongoing product development.
- International Market Progress: Rhythm's NDA filing in Japan has been accepted, with approval and launch expected by the end of 2026, further expanding its international presence and enhancing the company's global competitiveness.
See More
Rhythm Pharmaceuticals to Host Conference Call on Interim Phase 2 Results
- Interim Results Announcement: Rhythm Pharmaceuticals will host a conference call on June 13 to discuss interim six-month results from its Phase 2 trial for Prader-Willi syndrome, which is expected to attract attention from investors and healthcare professionals, potentially impacting the company's stock price.
- Leadership Participation: The call will feature insights from CEO David Meeker, M.D., and Dr. Jennifer Miller from the University of Florida, enhancing market confidence in the company's clinical progress and possibly fostering positive investor sentiment about future prospects.
- IMCIVREE Drug Information: Rhythm's lead asset, IMCIVREE, has received FDA approval for treating obesity related to genetic conditions, and this meeting is anticipated to clarify its market applications, potentially driving sales growth.
- Clinical Development Plans: The company is advancing clinical development for IMCIVREE in other rare diseases, showcasing its innovative capabilities in the biopharmaceutical sector, which may lay the groundwork for future product line expansions.
See More
Rhythm Pharmaceuticals Reports Positive Phase 2 Results for PWS Treatment
- Clinical Trial Results: In a trial involving 17 patients with Prader-Willi syndrome (PWS), treatment with setmelanotide resulted in a mean BMI reduction of 3.06%, with 6 out of 10 adult patients achieving over 2.5% BMI reduction, indicating the therapy's effectiveness in weight management and potential improvement in patients' quality of life.
- Body Composition Improvement: Among 16 patients assessed via DEXA scans, setmelanotide led to a mean gain of 0.74% in lean mass and a mean loss of 4.19% in fat mass, demonstrating the drug's ability to facilitate weight loss while preserving muscle mass, thereby enhancing overall health outcomes for patients.
- Emotional and Behavioral Improvements: Of the 15 patients with baseline anxiety scores above 11, 10 achieved significant improvements in anxiety and emotional distress measures, suggesting the therapy's potential to alleviate psychological burdens for both patients and their caregivers.
- Future Development Plans: Following these positive results, Rhythm Pharmaceuticals intends to advance setmelanotide into Phase 3 trials for PWS, further validating its long-term efficacy and safety, reflecting the company's strategic commitment to addressing rare diseases.
See More
Stock Investment Opportunities in May
- TransMedics' Bright Outlook: Despite TransMedics Group (NASDAQ: TMDX) reporting Q1 earnings per share of $0.30, below the expected $0.61, its revenue increased by 21% year-over-year, indicating strong long-term potential in organ transplant technology, especially with plans for European expansion.
- Rhythm Pharmaceuticals' Recovery: Rhythm Pharmaceuticals (NASDAQ: RYTM) recently secured FDA and European Commission approvals for Imcivree, which is expected to boost its stock price, while Japanese regulators are also reviewing the drug, impacting over 25,000 patients and highlighting significant market potential.
- Enbridge's Stable Returns: Enbridge (NYSE: ENB), as North America's largest natural gas utility, transports 30% of crude oil and one-fifth of natural gas, providing stable investment returns, with an attractive 5.2% dividend yield that stands out in the energy sector.
- Long-Term Growth Opportunities: Enbridge's management anticipates approximately $50 billion in growth opportunities by 2030, with investment decisions for $10 billion to $20 billion expected in the next 24 months, offering solid growth prospects despite being less explosive than TransMedics and Rhythm.
See More
Rhythm Pharmaceuticals Reports Strong Earnings, IMCIVREE Demand Surges
- Earnings Beat Expectations: Rhythm Pharmaceuticals reported quarterly earnings that exceeded market expectations, reflecting strong performance in drug sales, which is likely to boost investor confidence moving forward.
- Strong Demand for IMCIVREE: The demand for IMCIVREE continues to grow, driving revenue increases and indicating a rising market acceptance of the drug in the treatment landscape, potentially laying the groundwork for future revenue growth.
- International Market Expansion Potential: The company plans to launch IMCIVREE in Europe and Japan, and successful entry into these markets could significantly broaden its international business footprint and enhance its competitive position globally.
- Strategic Growth Outlook: Rhythm Pharmaceuticals' robust performance and international expansion plans suggest that its strategic decisions to meet global patient needs will contribute to long-term growth and an increase in market share.
See More
Rhythm Pharmaceuticals Surges 8% After Strong Quarterly Earnings Report
- Significant Revenue Growth: Rhythm Pharmaceuticals reported a nearly doubled revenue of $60.1 million in Q1, driven by its Imcivree drug, surpassing the analyst consensus estimate of $57 million, indicating strong market performance in the weight-loss sector.
- Improved Net Loss: The company's net loss widened to $56.7 million (or $0.83 per share), yet it was better than the expected loss of $0.86, suggesting some progress in cost management despite increased expenses.
- Accelerated Market Promotion: Following FDA approval for a new indication (hypothalamic obesity), Imcivree received over 150 patient start forms within six weeks, demonstrating robust market demand and rapid promotional capabilities.
- Strong European Market Performance: Rhythm's revenue in Europe surged by 27% quarter-over-quarter, primarily driven by strong demand in key markets like Germany and France, further boosting investor confidence in the company's growth prospects.
See More
Rhythm Pharmaceuticals Q1 2026 Earnings Call Highlights
- Revenue Growth: Rhythm Pharmaceuticals reported global net revenues of $60.1 million for Q1 2026, reflecting a 5% sequential increase from Q4 2025, indicating robust market performance, particularly with 61% of revenue generated in the U.S.
- IMCIVREE Launch Status: Since the FDA approval of IMCIVREE, the company has received over 150 start forms, with approximately 80% coming from new prescribers, demonstrating strong market reception and potential for future revenue growth.
- R&D and Expense Outlook: The company anticipates non-GAAP operating expenses for fiscal year 2026 to be between $385 million and $415 million, with R&D expenses projected at $197 million to $213 million, reflecting a commitment to ongoing product development.
- International Market Progress: Rhythm's NDA filing in Japan has been accepted, with approval and launch expected by the end of 2026, further expanding its international presence and enhancing the company's global competitiveness.
See More
